20:15 , Jun 15, 2018 |  BC Week In Review  |  Financial News

Aivita raises $15M series B, considers Korean clinical trial for cancer therapy

Cellular therapy company Aivita Biomedical Inc. (Irvine, Calif.) raised $15 million on June 11 in a series B round led by sole South Korean investor SFC Co. Ltd. (KOSDAQ:112240). The round gives it a cash...
18:23 , May 25, 2018 |  BC Week In Review  |  Clinical News

Dendreon takes Provenge earlier in prostate cancer

Dendreon Pharmaceuticals LLC announced it will study Provenge sipuleucel-T to prevent progression in men undergoing active surveillance for prostate cancer. Provenge comprises autologous dendritic cells loaded with a fusion protein of prostatic acid phosphatase and an...
15:04 , May 18, 2018 |  BC Extra  |  Clinical News

Dendreon takes Provenge earlier in prostate cancer

Dendreon Pharmaceuticals LLC announced it will study Provenge sipuleucel-T to prevent progression in men undergoing active surveillance for prostate cancer. Provenge comprises autologous dendritic cells loaded with a fusion protein of prostatic acid phosphatase and an...
00:54 , Mar 10, 2018 |  BioCentury  |  Product Development

Defining progress

Erleada apalutamide’s landmark approval established a new primary endpoint in prostate cancer that shortens the time it takes to run the trials by up to five years, and paves the way for treating disease before...
18:45 , Jul 6, 2017 |  BC Week In Review  |  Company News

Sanpower completes acquisition of Dendreon from Valeant

Sanpower Group Co. Ltd. (Nanjing, China) completed the purchase of Dendreon Pharmaceuticals Inc. from Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) for $819.9 million in cash. In February 2015, Valeant acquired bankrupt Dendreon's assets, including global rights...
23:15 , Jun 30, 2017 |  BC Extra  |  Company News

Sanpower completes Dendreon acquisition

Sanpower Group Co. Ltd. (Nanjing, China) said it completed the purchase of Dendreon Pharmaceuticals Inc. from Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) for $819.9 million in cash. In February 2015, Valeant acquired bankrupt Dendreon's assets,...
22:06 , May 11, 2017 |  BC Innovations  |  Tools & Techniques

Stemming the tide

OncoMed’s bad April has all the hallmarks of a death knell for the once-promising technology of cancer stem cells, adding to the pile of preclinical breakthroughs that didn’t translate to the clinic. But many insiders...
22:49 , Feb 8, 2017 |  BC Week In Review  |  Clinical News

DCVax-L: Ph III ongoing

Northwest Biotherapeutics said FDA lifted the partial clinical hold on a double-blind, placebo-controlled, international Phase III trial evaluating intradermal DCVax-L given at days 0, 10 and 20 and weeks 8, 16, 32, 48, 72, 96...
19:50 , Jan 13, 2017 |  BC Week In Review  |  Company News

Valeant, Sanpower deal

Valeant is selling cancer company Dendreon Pharmaceuticals Inc. to Sanpower for $819.9 million in cash. Valeant expects the deal to close next quarter. In February 2015, Valeant acquired bankrupt Dendreon's assets, including global rights to...
23:58 , Jan 10, 2017 |  BC Extra  |  Company News

Valeant selling Dendreon to Chinese conglomerate

Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) is selling cancer company Dendreon Pharmaceuticals Inc. to Sanpower Group Co. Ltd. (Nanjing, China) for $819.9 million in cash. Valeant expects the deal to close this half. In February 2015,...